NARRATIVE REVIEW OF THE EFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV-HBV COINFECTION
DOI:
https://doi.org/10.36387/phqp4b95Keywords:
Hepatitis B, HIV, Interferon alfa, Nucleos(t)ide analoguesAbstract
HIV-HBV coinfection remains a major global health challenge associated with increased morbidity and mortality. Various studies have evaluated the effectiveness and safety of antiviral therapies in coinfected patients; however, the findings remain inconsistent. This narrative review aimed to summarize the current evidence regarding the effectiveness and safety of antiretroviral therapy in patients with HIV-HBV coinfection. Literature searches were conducted through PubMed and Google Scholar for studies published between 2014 and 2025 using keywords related to HIV, hepatitis B, nucleos(t)ide analogues, interferon alfa, effectiveness, and safety. The findings demonstrated that the TLD regimen (tenofovir, lamivudine, and dolutegravir) showed superior virological outcomes compared with TLE (tenofovir, lamivudine, and efavirenz), including higher viral suppression rates and greater CD4 cell recovery. Nucleos(t)ide analogues such as entecavir and telbivudine effectively reduced HBV DNA levels and improved liver function markers. However, several adverse drug reactions were reported, including dizziness, nausea, vomiting, metabolic disturbances, and renal impairment, particularly with tenofovir-containing regimens. Interferon alfa also demonstrated potential benefits in enhancing seroconversion. Overall, TLD is considered the preferred regimen due to its superior efficacy and resistance profile, although careful monitoring for adverse effects remains essential.
References
1. Organization WH. Global HIV statistics and hepatitis B burden estimates. Geneva: World Health Organization; 2024.
2. Indonesia KKR. Pedoman nasional tatalaksana hepatitis B di Indonesia. Jakarta: Kementerian Kesehatan RI; 2017.
3. Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1):5. doi:10.1186/s41073-019-0064-8
4. Sari PAK, Widiastuti R, Azmi NA. Analisis efektivitas regimen terapi antiretroviral terhadap status viral load pada pasien HIV di Puskesmas Umbulharjo 1 dan Gedongtengen. Vol. 8. 2025;8(1):70–8. doi:10.35473/ijpnp.v8i01.4001
5. Susanti D, Nuryastuti T, Ikawati Z. Gambaran efektivitas terapi antiretroviral paduan rejimen TLD (Tenofovir + Lamivudin + Dolutegravir) pada pasien HIV di RSUP Dr. Mohammad Hoesin Palembang. Majalah Farmaseutik. 2024;20(3):299–308. doi:10.22146/farmaseutik.v20i3.85797
6. Suárez-García I. Long-term tolerability and effectiveness of dolutegravir/lamivudine in treatment-naive people with HIV. J Antimicrob Chemother. 2025. doi:10.1093/jac/dkae456
7. Sulaiman A, Lesmana LA, Nafrialdi, Helyanna. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B. Acta Med Indones. 2014;46(1):38–44.
8. Chow N. Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion. Clin Infect Dis. 2023. doi:10.1093/cid/ciac383
9. Gani RA. Perbandingan profil keamanan tenofovir dan telbivudin terhadap fungsi ginjal pada pasien hepatitis B di Indonesia. J Penyakit Dalam Indonesia. 2018. doi:10.7454/jpdi.v5i3.213
10. Ridruejo E. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. Ann Hepatol. 2014. doi:10.1016/S1665-2681(19)30861-0
11. Zhang W. Early clinical efficacy of pegylated interferon treatment in chronic HBV infection. J Viral Hepat. 2023. doi:10.1111/jvh.13792
12. Chi H. Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos(t)ide analogue. J Infect Dis. 2017;215(7):1085–93. doi:10.1093/infdis/jix024
13. Li Y. Efficacy of short-term peg-IFN α-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels. Virol J. 2024. doi:10.1186/s12985-024-02512-w
14. Putrinda IO. Evaluasi penggunaan obat dan efek sampingnya pada penderita HIV/AIDS di salah satu rumah sakit di Kota Tasikmalaya. Pros Semin Nas Diseminasi Hasil Penelitian Program Studi S1 Farmasi. 2022.
15. Yakut A. The relationship between the use of nucleos(t)ide analogs and metabolic parameters in patients with chronic hepatitis B. Eur Rev Med Pharmacol Sci. 2023. doi:10.26355/eurrev_202310_33959
16. Liu H. Inflammation and YMDD mutational patterns in lamivudine therapy for hepatitis B virus. Front Pharmacol. 2021. doi:10.3389/fphar.2021.648170
17. Indonesia KKR. Pedoman nasional penatalaksanaan HIV/AIDS. Jakarta: Kementerian Kesehatan RI; 2022.
18. Astuti T, Panduwiguna I, Nugrahini L. Kerasionalan penggunaan obat ARV pada pasien ODHA di Rumah Sakit Umum Daerah Kota Tangerang periode Oktober–Desember 2022. J Farm Kryonaut. 2024;3(1):11–6. doi:10.59969/jfk.v3i1.35
19. Organization WH. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. Geneva: World Health Organization; 2022.
20. Prasetiawati R. Studi in silico senyawa yang terkandung di dalam rimpang temulawak (Curcuma xanthorriza Roxb.) sebagai antihepatitis B. J Insan Farm Indonesia. 2021. doi:10.36387/jifi.v4i2.788
21. Sari PAK. Analisis efektivitas regimen terapi antiretroviral terhadap status viral load pada pasien HIV di Puskesmas Umbulharjo 1 dan Gedongtengen. IJPnP. 2025. doi:10.35473/ijpnp.v8i01.4001
22. Yasykurah MM. Penatalaksanaan hepatitis B: kajian pustaka. J Kesehatan Tambusai. 2024 doi:10.31004/jkt.v5i4.35930.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jurnal Insan Farmasi Indonesia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
